Correlation Between Puma Biotechnology and Rani Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Puma Biotechnology and Rani Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Puma Biotechnology and Rani Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Puma Biotechnology and Rani Therapeutics Holdings, you can compare the effects of market volatilities on Puma Biotechnology and Rani Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Puma Biotechnology with a short position of Rani Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Puma Biotechnology and Rani Therapeutics.

Diversification Opportunities for Puma Biotechnology and Rani Therapeutics

-0.17
  Correlation Coefficient

Good diversification

The 3 months correlation between Puma and Rani is -0.17. Overlapping area represents the amount of risk that can be diversified away by holding Puma Biotechnology and Rani Therapeutics Holdings in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Rani Therapeutics and Puma Biotechnology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Puma Biotechnology are associated (or correlated) with Rani Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Rani Therapeutics has no effect on the direction of Puma Biotechnology i.e., Puma Biotechnology and Rani Therapeutics go up and down completely randomly.

Pair Corralation between Puma Biotechnology and Rani Therapeutics

Given the investment horizon of 90 days Puma Biotechnology is expected to generate 0.46 times more return on investment than Rani Therapeutics. However, Puma Biotechnology is 2.18 times less risky than Rani Therapeutics. It trades about 0.09 of its potential returns per unit of risk. Rani Therapeutics Holdings is currently generating about -0.02 per unit of risk. If you would invest  250.00  in Puma Biotechnology on September 18, 2024 and sell it today you would earn a total of  50.00  from holding Puma Biotechnology or generate 20.0% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Puma Biotechnology  vs.  Rani Therapeutics Holdings

 Performance 
       Timeline  
Puma Biotechnology 

Risk-Adjusted Performance

6 of 100

 
Weak
 
Strong
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Puma Biotechnology are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. Despite fairly unsteady basic indicators, Puma Biotechnology demonstrated solid returns over the last few months and may actually be approaching a breakup point.
Rani Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Rani Therapeutics Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest inconsistent performance, the Stock's basic indicators remain strong and the recent confusion on Wall Street may also be a sign of long-lasting gains for the firm traders.

Puma Biotechnology and Rani Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Puma Biotechnology and Rani Therapeutics

The main advantage of trading using opposite Puma Biotechnology and Rani Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Puma Biotechnology position performs unexpectedly, Rani Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Rani Therapeutics will offset losses from the drop in Rani Therapeutics' long position.
The idea behind Puma Biotechnology and Rani Therapeutics Holdings pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Other Complementary Tools

Bonds Directory
Find actively traded corporate debentures issued by US companies
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories